In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Jiaoting EDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, P. R. China.ORCID 0009-0000-0134-3775 Yuxuan ZhaoKey Laboratory of Superlight Materials and Surface Technology, Ministry of Education, College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin 150001, P. R. China.ORCID 0009-0000-5388-5146 Xiaoling ZhangDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, P. R. China.ORCID 0000-0002-4835-8648 Qiuqi ZhangDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, P. R. China.ORCID 0009-0009-8706-0156 Ying XuDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, P. R. China.ORCID 0009-0000-5039-507X Shanshan LiuDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, P. R. China.ORCID 0009-0001-8570-7763 He DingKey Laboratory of Superlight Materials and Surface Technology, Ministry of Education, College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin 150001, P. R. China.ORCID 0000-0002-2371-5119 Jiuxin ZhuDepartment of Pharmacology (State-Province Key Laboratories of Biomedicine Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150086, P. R. China.ORCID 0000-0003-4215-4502 Piaoping YangKey Laboratory of Superlight Materials and Surface Technology, Ministry of Education, College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin 150001, P. R. China.ORCID 0000-0002-9555-1803 Rui XieDepartment of Digestive Internal Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, P. R. China.ORCID 0000-0003-0357-6702 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Hepatocellular carcinoma (HCC) remains a challenge for therapeutic efficacy in converting cold tumors into hot ones. Herein, doping defect-engineered manganese perovskite piezoelectric nanocubes (Mn-BaZrO
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsMembrane ProteinsNanoparticlesNecroptosisAnimalsApoptosisCell Line, TumorcGAS-STING Signaling PathwayHumansMiceReactive Oxygen SpeciesSTING ProteinMembrane ProteinsReactive Oxygen SpeciesSTING1 protein, humanSTING Protein
Identifiers
PMID42308311
PMCPMC13274619
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390